Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
SNSoligenix, Inc. logo

Soligenix, Inc. (SNGX)

NASDAQ Capital Market · Currency in USD
$0.37 ▲ +0.00 (+0.14%)
At close: Oct 23, 4:00 PM ET. Market closed.
$0.36 ▼ 0.00 (-0.93%)
After hours: Oct 23, 7:22 PM ET

Summary

Previous Close
$0.36
Open
$0.35
Day's Range
$0.35 – $0.37
52 Week Range
$0.28 – $1.70
Volume
125,963
Avg. Volume
5,303,630
Market Cap
$7.94M
Beta (5Y Monthly)
2.00
PE Ratio (TTM)
--
EPS (TTM)
-$0.64
Earnings Date
Nov 6, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
--

Profile: Soligenix, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
14
CEO
Christopher J. Schaber

Soligenix, Inc., a biopharmaceutical firm in its advanced development stages, concentrates on bringing innovative products to market within the United States, specifically targeting rare illnesses. The company's operations are divided into two main divisions: Specialized BioTherapeutics and Public Health Solutions. Within the Specialized BioTherapeutics division, Soligenix is advancing SGX301 (marketed as HyBryte), a novel photodynamic treatment that has successfully completed its Phase III clinical trials for managing cutaneous T-cell lymphoma.

Earnings

Next report: Fri, Nov 6, 2026
EPS estimate -$0.12
DateEst.Actual
Aug 7, 2026-$0.16-$0.12Beat
May 8, 2026-$0.30-$0.28Beat
Apr 3, 2026-$0.27$0.32Beat
Nov 7, 2025-$0.63-$0.58Beat
Aug 14, 2025-$0.79-$0.82Miss
May 9, 2025-$0.67-$1.06Miss

Analyst view

Rating: Buy
Buy 63% · Hold 38% · Sell 0%

Get free alerts on SNGX and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.